Kim Chong Hwa MD,PhD Sejong general hospital, Division of endocrine & metabolism
|
|
- Paula Williams
- 5 years ago
- Views:
Transcription
1 Kim Chong Hwa MD,PhD Sejong general hospital, Division of endocrine & metabolism
2
3 Contetns Prevalence of DPN Clinical impacts of DPN Managements of DPN
4 Prevalence of Diabetic peripheral neuropathy in Korea DPN(+) DPN DPN(-) DPN(+) DPN DPN(-) 46% 54% 67% 33% N = 875, (%) N = 3999, (%) Diabetic DSPN patient survey,2005 Kim CH et al. 8 th IDF-WPR, 2010
5
6 Painful Diabetic Neuropathy is More Than Pain Alone Do Patients With DPNP Have High Rates of Anxiety, Mood and Sleep Difficulties? and, does this overlap impact patient lives and clinical outcomes?
7 Clinical Consequences of Diabetic P eripheral Neuropathy (DPN) Symptomatic Neuropathy Pathogenic Pain Burning Paresthesia Hyperesthesia Allodynia Nocturnal exacerbation Autonomic Orthostatic hypotension Cardiac autonomic neuropathy Gastroparesis Diarrhea Constipation Incontinence Erectile dysfunction Quality of life Insensitivity Foot ulceration Infection Amputation Falls Charcot foot
8 DSPN: Impact on the quality of life Personal Relationship Leisure Occupational activity Daily activity Walking Sleep Mood 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Diabetic DSPN patient survey,2005 N = 472, (%)
9 Multidimensionality of DPNP Anxiety Depression Anger Fear Loss of conf idence Psychological CVA = Cerebrovascular accident; IHD = Ischaemic heart disease; PVD = Peripheral vascular disease.
10 Multidimensionality of DPNP Anxiety Depression Anger Fear Loss of conf idence Psychological Social Job loss Marital disha rmony Isolation Loss of socia l status CVA = Cerebrovascular accident; IHD = Ischaemic heart disease; PVD = Peripheral vascular disease.
11 Important consideration for NICE! Anxiety Depression Anger Fear Loss of conf idence Obesity Psychological Social Job loss Marital disha rmony Isolation Loss of socia l status Visual loss Nephropathy Ulcers Unsteadiness and Falls Autonomic n europathy Vasculopathy PVD/IHD/CVA CVA = Cerebrovascular accident; IHD = Ischaemic heart disease; PVD = Peripheral vascular disease.
12 Frequency of Comorbidities Record ed Within Selected Nations DPN Patients (%) France Italy Spain UK CHD=Coronary heart disease. Rubino A, et al. Prim Care Diabetes. 2007;1:129 34
13 Risk Factors for Incident Neuropathy: Model 1: Without cardiovascular disease and retinopathy Hypertension History of Smoking 1.38 Hb A1c 1.48 Change in Hb A1c 1.36 Diabetes duration BMI Triglycerides Total cholesterol The EURODIAB PCS Odds ratios (95% CI) N=1,101 with Type 1 DM; Follow-up: 7.3±0.6 years *p=0.03; **p=0.001; ***p< BMI = Body mass index; CI = Confidence interval; Hb A1c = Glycated hemoglobin; PCS = Prospective complications study. Tesfaye S, et al. N Engl J Med. 2005;352: * *** * *** ** *** * 3 4
14 Treatment based on four cornerstones Causal treatment aimed at (near) normoglycemia Treatment based on pathogenetic mechanisms Symptomatic treatment Avoidance of risk factors and complications
15 DCCT: Effect of intensive vs conventional glycemic control on neuropathy in type 1 diabetes
16 Effect of long-term intensive insulin vs conventional control on peripheral neuropathy in T2DM (cont)
17 The indirect evidence in treating TG for reducing DPNP Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study) - Lancet 2009
18 ACCORD Intensive therapy did not reduce the risk of advanced measures of microvascular outcomes, but delayed the onset of albuminuria and some measures of eye complications and neuropathy. Lancet Vol 376 August 7, 2010
19 DPN: Treatment N = 472, (%) Unkown, 1% No, 52% Yes, 47% Others Opiod analgesics γ-linoleic acid Anticonvulsant Antidepressant Alpha lipoic acid N = 222, (%) 0% 10% 20% 30% 40% 50% N = 1338, (%) Diabetic DSPN patient survey,2005 Kim CH et al. 8 th IDF-WPR, 2010
20 Treatment of DPNP up to 2003 Near normoglycemia (Hb A1c 6 7%) 1,2 Tricyclic compounds/ssris 1 Anticonvulsants 1,2 Carbamazepine Gabapentin Tramadol, oxycodone 1,3,4 Capsaicin 1 TENS, acupuncture, ESCS etc. 1,5 ESCS = Epidural spinal cord stimulation; TENS = Transcutaneous electrical nerve stimulation. 1. Tesfaye S, Kempler P. Diabetologia. 2005;48: ; 2. Backonja M, et al. JAMA. 1998;280: ; 3. Gimbel JS, et al. Neurology. 2003;60: ; 4. Watson CP, et al. Pain. 2003; 105:71 78; 5. Tesfaye S, et al. Lancet. 1996;348:
21 SNRIs New Medications for Painful DPN ( ) Duloxetine indicated for painful DPN Venlafaxine Anticonvulsants Pregabalin indicated for painful DPN Topiramate Oxcarbazepine Lamotrigine Sodium Valproate Lacosamide Botulinum Toxin VEGF gene transfer Actovegin Sativex (cannabis) α-lipoic acid SNRI = serotonin noradrenaline reuptake inhibitor
22 Improvement Duloxetine Improves 24-Hour Average Pain Severity in DPNP Mean baseline score 5.83 Mean Change in 24-hour Average Pain Severity Score * * 1.5 * 2.0 * * * * * * * 2.5 * * * * * * * * 3.0 * * * * * * Time (Weeks) MMRM = Mixed model repeated measures. 1. Goldstein D, et al. Pain. 2005;116: ; 2. Wernicke J, et al. J Pain. 2004;5:S48; 3. Raskin J, et al. Pain Medicine. 2005;6: Placebo (n=330) Duloxetine 20 mg QD (n=111) Duloxetine 60 mg QD (n=334) Duloxetine 60 mg BID (n=333) *p 0.05 vs placebo MMRM Pooled data from 3 studies
23 Most Common Adverse Events Associated with Duloxetine in DPNP Duloxetine Adverse Events that Occurred 5% and Twice Placebo Incidence of Adverse Events (%) Placebo (n=339) Duloxetine 20 mg/day (n=115) Duloxetine 60 mg/day (n=334) Duloxetine 120 mg/day (n=341) Pooled data from 3 studies Duration* 6 days 4 days Duration* * Median duration data: 14 days 23 days Duration* 5 days 5 days Duloxetine (60 mg and 120 mg) Placebo Nausea Somnolence Dizziness Constipation Sweating Dry Mouth Appetite Robinson M, et al. Presented at: 8th International Conference on the Mechanisms and Treatment of Neuropathic Pain; 5 Nov 2005; San Francisco, CA, USA.
24 Duloxetine Improves Response Rates in DPNP After 12 weeks 30% Reduction in 24-hour Average Pain 50% Reduction in 24-hour Average Pain Patients (%) ** ** ** *** *** ** Patients (%) * *** *** *** * ** 0 0 Study 1 1 Study 2 3 Study 3 1 Study 1 2 Study 2 3 Study 3 4 Placebo Duloxetine 20 mg QD Duloxetine 60 mg QD Duloxetine 60 mg BID * p<0.05 vs placebo ** p<0.01 vs placebo *** p<0.001 vs placebo 1. Presentation: Raskin J, et al. 41st European Association for the Study of Diabetes (EASD) Annual Meeting; Athens, Greece, September 12 15, 2005; 2. Goldstein DJ, et al. Pain. 2005;116: ; 3. Wernicke JF, et al. Neurology. 2006;67: ; 4. Raskin J, et al. Pain Med. 2005;6:
25 Duloxetine Decreased the Impact of Pain on Daily Activity, Function and Enjoyment of Life (BPI-I) Decreased Impact/Improvement Pooled data from 3 studies LS Mean Change from Baseline BPI-I Score BPI Avg Score General Activity *** *** *** *** Mood *** *** BPI = Brief pain inventory; LS = Least squares. Armstrong DG, et al. Pain Med. 2007;8: Walking Ability *** *** Normal Work ** *** Placebo Duloxetine 60 mg QD Duloxetine 60 mg BID Relationship With Others * *** Sleep Enjoyment of Life ** *** *** * p<0.05 vs placebo ** p<0.01 vs placebo *** p<0.001 vs placebo ***
26 Pregabalin for Painful DPN Pregabalin 300 mg/day and 600 mg/day improved SF-MPQ and sleep interference, and improved some domains of the SF-36 Least-squares Mean Pain Score * Placebo (n=115) Pregabalin 75 mg (n=77) Pregabalin 300 mg (n=81) Pregabalin 600 mg (n=81) * * Time (Weeks) * * *** ** *p= vs placebo **p< vs placebo ***p<0.001 vs placebo 5 SF-MPQ = Short-form McGill Pain Questionnaire; SF-36 = Short-Form 36 Quality-of-Life Questionnaire. Lesser H, et al. Neurology. 2004;63:
27 Pregabalin: Adverse Events Adverse Placebo Pregabalin Pregabalin event (%) (n=97) 300 mg/day (n=81) 600 mg/day (n=82) Dizziness Somnolence Edema Amblyopia Ataxia Confusion Constipation Lesser H, et al. Neurology. 2004;63:
28 Pregabalin: Proportion of Patients Meeting 50% and 30% Improvement in Mean Pain Score Responders (%) % Improvement from Baseline 30% Improvement from Baseline Placebo (n=550) Pregabalin 150 mg (n=175) Pregabalin 300 mg (n=265) Pregabalin 600 mg (n=507) NNT 300 mg= mg=4.0 NNT = Number needed to treat. Freeman R, et al. Diabetes Care. 2008;31:
29 Number Needed to Treat (NNTs) for >50% Pain Reduction Tricyclic Antidepressants 397 Valproate 83 Carbamazepine/Lamotrigine/Phenytoin 109 Opioids 149 Tramadol Gabapentin/Pregabalin Antidepressants, SNRI Mexiletine* NMDA Antagonists* Capsaicin Antidepressants, SSRI Topiramate* Topical Lidocaine N/A Approximately 1/3 Pain Relief >50% *At least half of the conducted trials showed no significant effect NMDA = N-methyl-D-aspartic acid. Jensen TS, et al. Diab Vasc Dis Res. 2006;3: NNT
30 Treatment Algorithm for PDN Painful diabetic neuropathy Consideration of contraindications and comorbidities α 2 -δ agonist (pregabalin or gabapentin) TCA SNRI (duloxetine) If pain control is inadequate and considering contraindications TCA or SNRI SNRI or α 2 -δ agonist (pregabalin or gabapentin) TCA or α 2 -δ agonist (pregabalin or gabapentin) If pain control is still inadequate Add opioid agonist as combination therapy PDN = Peripheral diabetic neuropathy; SNRI = Serotonin-norepinephrine reuptake inhibitor; TCA = Tricyclic antidepressants. Tesfaye et al. Diabetes Care 2010; 33:
31 Pathogenesis of DPN Dyslipidemia Diabetes EFA dysmetabolism Polyol pathway flux ARIs Antioxidants α -Lipoic acid NEUROPATHY A-V shunting Hyperglycemia PKCß Free transition metal ions Inhibitor Autoxidation AGE formation Endogenous scavengers Reactive Oxygen Species Ischemia/ reperfusion AGE Inhibitors Nerve and ganglion blood flow ONOO - Endoneurial hypoxia DAG PKC ß AII ACE-I., ARB ET C-Peptide NO PGI 2 EDHF Vascular dysfunction Linoleic acid GLA DGLA AA GLA Modified from Cameron et al., Diabetologia, 2001
32 Treatment of diabetic neuropathy based on the putative pathogenetic mechanisms Ziegler D. Diabetes Care 31 (Suppl.2): S255-S261, 2008
33 Conclusions Patients With DPNP Have High Rates of Anxiety, Mood and Sleep Difficulties Symptomatic treatments only relieve pain without targeting the underlying neuropathy, which is associated with a poor prognosis (ulcers, amputations). Pathogenic treatments may be added, given its safety and potential for improving neuropathic symptoms Therefore, treatment based on the combination of symptomatic and pathogenetic mechanisms of DPN, which would be effective despite persisting hyperglycemia, is preferred.
Practical upates in Diabetes & CV risk management: Brief Updates Neurological complications in diabetes
Practical upates in Diabetes & CV risk management: Brief Updates Neurological complications in diabetes Slides presented during CDMC in Almaty, Kazakhstan on Sunday April 13, 2014 and prepared by: Boris
More informationMANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.
MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D. The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial
More informationDiabetic Neuropathy New Insights and a Paradigm Shift
Diabetic Neuropathy New Insights and a Paradigm Shift Professor Solomon Tesfaye MB ChB, MD, FRCP Research Lead - Academic Directorate of Diabetes & Endocrinology Sheffield Teaching Hospitals and University
More informationpdpn early screening and management
pdpn early screening and management The Hidden Faces of Diabetes Summit was held in Johannesburg, South Africa, from 20 to 21 September 2014. Organized by Pfizer Middle East and Africa, the interactive
More informationDiabetic Peripheral Neuropathic Pain: Evaluating Treatment Options
Diabetic Peripheral Neuropathic Pain: Evaluating Treatment Options Ramon L. Cuevas-Trisan, MD Disclosures Speakers Bureau/Honoraria: Allergan, Ipsen 1 Learning Objectives Discuss practical approaches to
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationApproaches to Managing Neuropathic Pain. Nov 7, 2017
1 Approaches to Managing Neuropathic Pain Nov 7, 2017 3 Learning objectives Review the current Canadian Guidelines on Neuropathic Pain Review the diagnosis and options available for the management of Neuropathic
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationDiabetic Peripheral Neuropathy: Assessment and Treatment
Diabetic Peripheral Neuropathy: Assessment and Treatment Denise Soltow Hershey PhD, FNP-BC Michigan Council of Nurse Practitioners Annual Conference March 17, 2018 Objectives 1) Describe the clinical features
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More information5.9. Rehabilitation to Improve Central Pain
5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...
More informationMedications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
More informationPharmacologic Management Part 1: Better-Studied Neuropathic Pain Diseases
PAIN MEDICINE Volume 5 Number S1 2004 Pharmacologic Management Part 1: Better-Studied Neuropathic Pain Diseases Misha-Miroslav Backonja, MD,* Jordi Serra, MD *University of Wisconsin Hospital and Clinics,
More informationNeuropathic Pain in Palliative Care
Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic
More informationScottish Medicines Consortium
Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed
More informationDiabetic Retinopathy and Neuropathy: 2018 Clinical Practice Guidelines
Diabetic Retinopathy and Neuropathy: 2018 Clinical Practice Guidelines Richard Arakaki, M.D. Phoenix Area Diabetes Consultant August 9 th 2018 Disclose no conflict of interest Complications and Co-morbidities
More informationRESEARCH. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review
Effects of s for symptoms of painful diabetic neuropathy: systematic review Man-chun Wong, pain management nurse, 1 Joanne W Y Chung, professor, 2 Thomas K S Wong, chair professor 2 1 Nursing Services
More informationThe clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines
The clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines Clin. Invest. (2012) 2(5), 483 489 Painful diabetic neuropathy (PDN) is highly
More informationExecutive Summary Pregabalin (Lyrica by Pfizer) Formulary Review
Executive Summary Pregabalin (Lyrica by Pfizer) Formulary Review Lyrica (pregabalin) is a new prescription medication indicated for use in painful diabetic peripheral neuropathy (DPN), post-herpetic neuralgia,
More informationThe World Health Organization (WHO) has described diabetes mellitus as Metabolic
1.1. Background The World Health Organization (WHO) has described diabetes mellitus as Metabolic disorder of multiple etiology characterized by chronic hyperglycemia with disturbances of carbohydrate,
More informationCANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Stroke Rehabilitation Evidence Tables Rehabilitation to Improve Central Pain
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Rehabilitation to Improve Central Pain Hebert, D, Teasell, R (Writing Group Chairs) on Behalf of the STROKE REHABILITATION Writing Group 2015 December 2015
More informationMedicinal product no longer authorised SCIENTIFIC DISCUSSION. London, 22 November 2007 Product Name : Ariclaim Procedure No: EMEA/H/C/000552/II/0024
European Medicines Agency Post-Authorisation Evaluation of Medicines for Human Use London, 22 November 2007 Product Name : Ariclaim Procedure No: EMEA/H/C/000552/II/0024 SCIENTIFIC DISCUSSION 1/7 EMEA
More informationManagement of Pain related to Spinal Cord Lesion
Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of
More informationI s s u e 1,
I s s u e 1, 2 0 1 4 Guidelines for the Pharmacological Treatment of Peripheral Neuropathic Pain: Expert Panel Recommendations for the Middle East Region EFNS guidelines on the pharmacological treatment
More informationIndex. Foot Ankle Clin N Am 11 (2006) Note: Page numbers of article titles are in boldface type.
Foot Ankle Clin N Am 11 (2006) 865 869 Index Note: Page numbers of article titles are in boldface type. A Alpha-lipoic acid, in diabetic neuropathy, 764 Amputation(s), lower-extremity, in diabetes, 791
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationDiabetes is associated with increased risk
DIABETIC PERIPHERAL NEUROPATHY: ADVANCES IN UNDERSTANDING AND TREATMENT * Vera Bril, MD, PhD, FRCP ABSTRACT Diabetic peripheral neuropathy (DPN) affects approximately 50% of patients with diabetes and
More informationJong Chul Won, 1 Yong-Jin Im, 2 Ji-Hyun Lee, 3 Chong Hwa Kim, 4 Hyuk Sang Kwon, 5 Bong-Yun Cha, 5 and Tae Sun Park 6. 1.
Hindawi Journal of Diabetes Research Volume 2017, Article ID 5751687, 9 pages https://doi.org/10.1155/2017/5751687 Research Article Clinical Phenotype of Diabetic Peripheral Neuropathy and Relation to
More informationNon-Opioid Drugs to Treat Neuropathic Pain. March 2018
Non-Opioid Drugs to Treat Neuropathic Pain Final Report March 2018 This report is intended only for state employees in states participating in the Drug Effectiveness Review Project (DERP). Do not distribute
More informationDiabetic Neuropathy. Nicholas J. Silvestri, M.D.
Diabetic Neuropathy Nicholas J. Silvestri, M.D. Types of Neuropathies Associated with Diabetes Mellitus p Chronic distal sensorimotor polyneuropathy p Focal compression neuropathies p Autonomic neuropathy
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationPeripheral neuropathy (PN)
Peripheral neuropathy (PN) damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic:
More informationPainful Diabetic Neuropathy Effective Management. Ketan Dhatariya Consultant in Diabetes NNUH
Painful Diabetic Neuropathy Effective Management Ketan Dhatariya Consultant in Diabetes NNUH Neuropathic Pain Prevalence varies between 10 and 90% depending on classification Accounts for 50-75% of non-traumatic
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More information8/28/2012. Disclosure. Accreditation. Neuropathic Pain: Overview and Management. Pharmacists: L01-P
Neuropathic Pain: Overview and Management Shyam Gelot, Pharm.D. Assistant Professor University of South Florida College of Pharmacy September 8, 2013 Disclosure I have nothing to disclose concerning possible
More informationNeuropathic Pain. Scott Magnuson, MD Pain Management of North Idaho, PLLC
Neuropathic Pain Scott Magnuson, MD Pain Management of North Idaho, PLLC Pain is our friend "An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders
More informationCONCORD INTERNAL MEDICINE. Peripheral Neuropathy. April 22, 2012
CONCORD INTERNAL MEDICINE Peripheral Neuropathy Douglas G. Kelling, Jr., MD C. Gismondi-Eagan, MD, FACP George C. Monroe, III, MD April 22, 2012 The information contained in this protocol should never
More informationKim Chong Hwa MD,PhD Sejong general hospital, Division of endocrine & metabolism
Kim Chong Hwa MD,PhD Sejong general hospital, Division of endocrine & metabolism st1 Classification and definition of diabetic neuropathies Painful diabetic peripheral neuropathy Diabetic autonomic neuropathy
More informationNeuropathic Pain. Griffith Research Online. Author. Published. Journal Title. Copyright Statement. Downloaded from. Link to published version
Griffith Research Online https://research-repository.griffith.edu.au Neuropathic Pain Author Hall, Tony Published 2010 Journal Title Australian Journal of Pharmacy Copyright Statement Copyright 2010 Australian
More informationSAFETY OF PREGABALIN, GABAPENTIN AND AMITRIPTYLINE IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY
85 P a g e International Standard Serial Number (ISSN): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences 4(3): May-June 2015 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND BIO SCIENCES
More informationSpinal Cord Injury Pain. Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018
Spinal Cord Injury Pain Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018 Objectives At the conclusion of this session, participants should be able to: 1. Understand the difference between nociceptive
More informationManaging the Chronic Pain Patient. (and some stuff about opioids)
Managing the Chronic Pain Patient. (and some stuff about opioids) C. Patrick Carroll, M.D. Assistant Professor Johns Hopkins University School of Medicine Department of Psychiatry and Behavioral Sciences
More informationsensory nerves, motor nerves, autonomic nerves
damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic: long term, begins subtly
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationLYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS
Volume 20, Issue 7 April 2005 LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS Tanja Lepir, Pharm.D. Candidate Nervous system dysfunction leading to neuropathic pain can occur from many causes: infection,
More informationHeadaches, 37, 42 Hypnotherapy, 101t, 106 Hypothalamic-pituitary-adrenal (HPA) axis, 59, 61, 63, 64, 65
INDEX Note: page numbers in italic typeface indicate figures. Page numbers followed by a t indicate tables. Abbreviations are for terms listed on pages 135-137. Acetaminophen/tramadol in fibromyalgia,
More information130/80 vs. 140/90 If nephropathy is present the target should be 120/ /10/07
DG van Zyl Macro vascular Micro vascular Neuropathy Infections Genetic susceptibility *Repeated acute changes in cellular metabolism Hyperglycemia Tissue damage **Cumulative long term changes in stable
More informationManaging Diabetic Peripheral Neuropathic Pain
Managing Diabetic Peripheral Neuropathic Pain Juzar Hooker Consulting Neurologist, Aga Khan University Hospital, Nairobi juzar.hooker@aku.edu Disclosure Eli lilly (have not driven, reviewed or controlled
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationARTICLE IN PRESS. Algorithm for neuropathic pain treatment: An evidence based proposal
Pain xx (2005) 1 17 www.elsevier.com/locate/pain Algorithm for neuropathic pain treatment: An evidence based proposal N.B. Finnerup a, *, M. Otto b,1, H.J. McQuay c,2, T.S. Jensen a,3, S.H. Sindrup b,4
More informationMædica - a Journal of Clinical Medicine. University of Oradea, Institute for Doctoral Studies, Oradea, Bihor County, Romania
MAEDICA a Journal of Clinical Medicine 2018; 13(3): 229-234 https://doi.org/10.26574/maedica.2018.13.3.229 Mædica - a Journal of Clinical Medicine Original paper Diabetic Neuropathy Prevalence and Its
More informationManagement of Neuropathic Pain
MANAGEMENT Goals of Treatment Management of Neuropathic Pain Diagnosis Improved physical functioning Improved psychological state Treatment of underlying conditions Pharmacological and non-pharmacological
More informationBEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN
BEYOND OPIOIDS: ADJUNCTS FOR TREATING PAIN Ronald Januchowski, D.O. 2017 Objectives By the end of the presentation, the learner should be able to: Summarize the risks of opiates when used for non-cancer
More informationNeuropathic pain (pain due to nerve damage)
Neuropathic pain (pain due to nerve damage) Clinical Guideline Pain can be nociceptive, neuropathic or mixed. The neuropathic component of pain generally responds poorly to conventional analgesics. Consider
More informationDr.Rahiminejad Roozbeh Hospital TUMS
Dr.Rahiminejad Roozbeh Hospital TUMS Psychiatric disorders, particularly depression, anxiety and eating disorders, are prevalent in diabetes. Mental illness increases risk of diabetes and diabetic complications.
More informationOther classical forms of neuropathic pain include diabetic peripheral neuropathy, trigeminal neuralgia and postherpetic
Guideline Name: Neuropathic Pain Neuropathic pain is defined by the International Association for the Study of Pain, Neuropathic Special Interest group as pain arising as a direct consequence of a lesion
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationPlease print clearly; illegible forms will delay your receiving credit/verification: City State ZIP. Yes No
PARTICIPANT INFORMATION Please print clearly; illegible forms will delay your receiving credit/verification: First Name MI Last Name Address 1 Address 2 City State ZIP Country Daytime Telephone Fax E-mail
More informationRecent advances in the management of diabetic distal symmetrical polyneuropathy
Recent advances in the management of diabetic distal symmetrical polyneuropathy Solomon Tesfaye* REVIEW ARTICLE ABSTRACT There is now little doubt that poor blood glucose control is an important risk factor
More informationREFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Neuropathic Pain (NP) in the US The US NP market was valued
More informationMicrovascular Complications
Comprehensive education course for Asian diabetes educators Microvascular Complications Keimyung University Dongsan Medical Center Mi Kyung Kim Conflict of interest disclosure None Committee of Scientific
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 03 Nov 2018 09:24:50 GMT) CTRI Number Last Modified On 10/06/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationOverview of Neuropathic pain
Overview of Neuropathic pain Kongkiat Kulkantrakorn,M.D. Neurology division Thammasat University 1 Contents Overview of pain New concepts and mechanism Treatment options New data in management 2 3 Breaking
More informationPAIN EDUCATION Module 5: Neuropathic pain
PAIN EDUCATION Module 5: Neuropathic pain 2013 Excerpta Medica BV The material presented in this teaching slide deck is for educational purposes only. If you wish to reproduce, transmit in any form or
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationPAINFUL DIABETIC NEUROPATHY
PAINFUL DIABETIC NEUROPATHY Content Painful diabetic neuropathy (PDN): painful consequences of diabetes Mechanisms of neuropathic pain in PDN Diagnosis and management of PDN PDN treatment: guidance from
More informationOptimizing Non-Opioid Therapy for Chronic Pain
Optimizing Non-Opioid Therapy for Chronic Pain Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means
More informationDrug Class Review Neuropathic Pain
Drug Class Review Neuropathic Pain Final Update 1 June 2011 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of reports is to make available information
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More informationMr. LBP: Case Presentation
CLINICAL CASES Case: Mr. LBP Mr. LBP: Case Presentation Mr. LBP is a 35-year-old male He fell down while participating in a recreational sports activity He subsequently developed low back pain Upon arrival
More informationWEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationSafety and Efficacy Review: Lacosamide for the Treatment of Diabetic Neuropathic Pain
Clinical Medicine Insights: Therapeutics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Safety and Efficacy Review: Lacosamide for the Treatment of
More informationGabapentin vs. Amitriptyline in Painful Diabetic Neuropathy: An Open-Label Pilot Study
280 Journal of Pain and Symptom Management Vol. 20 No. 4 October 2000 Original Article Gabapentin vs. Amitriptyline in Painful Diabetic Neuropathy: An Open-Label Pilot Study Carlo Dallocchio, MD, Carlo
More informationDisclosures. Objectives 9/8/2015
The Aftermath of the Decade of Pain: Alternatives to Opioids in Chronic Pain Management Julie Cunningham, PharmD, BCPP Disclosures No relevant financial disclosures I will discuss off-label uses of antiepileptics,
More informationClinical Policy Title: Diabetic neuropathy selected treatments
Clinical Policy Title: Diabetic neuropathy selected treatments Clinical Policy Number: 06.02.06 Effective Date: August 1, 2017 Initial Review Date: July 20, 2017 Most Recent Review Date: September 21,
More informationUnderstanding and Treating Post- Herpetic Neuralgia (PHN)
Understanding and Treating Post- Herpetic Neuralgia (PHN) Mary Lynn McPherson, Pharm.D., BCPS Professor University of Maryland School of Pharmacy mmcphers@rx.umaryland.edu This program has been supported
More informationMicrovascular Complications
Microvascular Complications in Diabetes Jyotika Fernandes. MD Professor Div of Endocrinology Endo Section Chief, RHJ VA Hospital Microvascular Complications Hyperglycemia Eye Kidney Nerves Retinopathy
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationPainful diabetic neuropathy
Rajinikanth Sundara Rajan MD FRCA EDRA Lorraine de Gray MD LLM (Medical Law) FRCA FFPMRCA Emad George MD FRCP (UK) PG Cert Med Ed Matrix reference 1A02, 2E03, 3E00 Key points Painful diabetic neuropathy
More informationIndian Journal of Basic and Applied Medical Research; March 2018, Vol.-7, Issue- 2, P
Original article: A Prospective, Randomized, open label, comparative study of Amitriptyline, Pregabalin and sodium Valproate in Patients with painful Diabetic neuropathy *Dr.T.Siyamala Devi, **Dr. S. Hariharan
More informationPalliative Care: Treatment at the End of Life
Page 1 Palliative Care: Treatment at the End of Life This webcast has been supported by an educational grant from Purdue Pharma L.P. Mary Lynn McPherson, Pharm.D., BCPS, CDE Professor, University of Maryland
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationStandards of Medical Care In Diabetes
Standards of Medical Care In Diabetes - 2017 Robert E. Ratner, MD, FACP, FACE Professor of Medicine Georgetown University School of Medicine Disclosed no conflict of interest Standards of Care Professional.diabetes.org/SOC
More informationPostherpetic neuralgia *
Section 1 Chapter 1 Neurological Disorders Postherpetic neuralgia * Alan David Kaye and Charles E. Argoff Case study A 78-year-old male with a history of postherpetic neuralgia (PHN) as well as hypertension
More informationPharmacological treatment of Pain
Pharmacological treatment of Pain None Disclosures and Conflict of Interest Dr John F. Flannery Medical Director MSK and Multisystem Rehab Program PMR - FRCPC Objectives At the end of this presentation
More informationPain Management in the
Pain Management in the Elderly Meri Hix, PharmD, CGP, BCPS Associate Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy No conflicts of interest to declare Objectives Discuss
More informationNeuropathic pain treatment: Guidelines
Neuropathic pain treatment: Guidelines HCN meeting Dec 2012 Troels Staehelin Jensen, MD, DMSc Dept. of Neurology & Danish Pain Research Center Aarhus University Hospital, Denmark Neuropathic Pain: Management
More informationA review of Neuropathic Pain: From Guidelines to Clinical Practice
Pain Ther (2017) 6 (Suppl 1):S35 S42 DOI 10.1007/s40122-017-0087-0 REVIEW A review of Neuropathic Pain: From Guidelines to Clinical Practice Giorgio Cruccu. Andrea Truini Received: October 12, 2017 Ó The
More informationDiabetes and the Elderly: Medication Considerations When Determining Benefits and Risks
Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More informationSteven Richeimer, M.D.
Steven Richeimer, M.D. Associate Professor of Anesthesiology & Psychiatry Chief, Division of Pain Medicine Keck School of Medicine, USC Los Angeles, CA 323-442-6202 www.helpforpain.com Pain Light touch
More informationBrian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD
Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD 1630 Main Street Suite 215 Chester, MD 410-571-9000 www.4-no-pain.com
More informationADJUVANT PAIN MANAGEMENT
ADJUVANT PAIN MANAGEMENT Bruce H. Chamberlain, MD FACP FAAHPM Palliative Consulting Orem, UT AAHPM Intensive Board Review Course Using Adjuvant Treatments for Chronic Pain Bruce H. Chamberlain, MD FACP
More information